title: Axonal protection by 17β-estradiol through thioredoxin-1 in tumor necrosis factor-induced optic neuropathy.
abstract: Axonal degeneration often leads to the death of neuronal cell bodies. Previous studies demonstrated the substantial protective role of 17β-estradiol (E2) in several types of neuron. However, most studies examined cell body protection, and the role of 17β-E2 in axonal degeneration of retinal ganglion cells (RGC) remains unclear. In this study, we showed the presence of thioredoxin-1 (Trx1) in the optic nerve axons and found that the levels of Trx1 protein were significantly decreased in isolated RGC and the optic nerve after intravitreal injection of TNF, which was shown previously to induce optic nerve degeneration and subsequent loss of RGC. These changes were concomitant with disorganization of the microtubules with neurofilament accumulation, which were blocked by 17β-E2 implantation. 17β-E2 treatment also totally abolished TNF-induced decreases in Trx1 protein levels in isolated RGC and the optic nerve. The induction of Trx1 by 17β-E2 in the optic nerve was significantly inhibited by simultaneous injection of Trx1 small interfering RNA (siRNA) with TNF. Up-regulation of Trx1 by 17β-E2 in RGC-5 cells was prevented by Trx1 siRNA treatment. 17β-E2 significantly prevented TNF-induced axonal loss, and this axonal-protective effect was inhibited by intravitreal injection of Trx1 siRNA. This finding was also supported by the quantification of microtubules and neurofilaments. These results suggest that a Trx1 decrease in RGC bodies and their axons may be associated with TNF-induced optic nerve axonal degeneration. Axonal protection by 17β-E2 may be related to its regulatory effect on Trx1 induction.
authors.affiliation: Department of Ophthalmology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. kitaoka@marianna-u.ac.jp
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kitaoka
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Munemasa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Junko
authors.initials: J
authors.lastname: Kuribayashi
authors.forename: Natsuko
authors.initials: N
authors.lastname: Koseki
authors.forename: Kaori
authors.initials: K
authors.lastname: Kojima
authors.forename: Toshio
authors.initials: T
authors.lastname: Kumai
authors.forename: Satoki
authors.initials: S
authors.lastname: Ueno
mesh_terms: D000818:Animals; D001369:Axons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D002470:Cell Survival; D002478:Cells, Cultured; D004958:Estradiol / Q000378:metabolism*; D005260:Female; D020868:Gene Silencing; D058449:Intravitreal Injections; D008870:Microtubules / Q000473:pathology; D009410:Nerve Degeneration / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000378:metabolism*; D009900:Optic Nerve / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009901:Optic Nerve Diseases / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D034741:RNA, Small Interfering; D051381:Rats; D017208:Rats, Wistar; D012165:Retinal Ganglion Cells / Q000378:metabolism / Q000473:pathology; D013879:Thioredoxins / Q000235:genetics / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000633:toxicity; D015854:Up-Regulation
chemical_list: D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D034741:RNA, Small Interfering; D014409:Tumor Necrosis Factor-alpha; C495697:Txn1 protein, rat; D004958:Estradiol; D013879:Thioredoxins